The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
Abstract
OBJECTIVE: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs). METHODS: Data were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but different inclusion criteria were applied with regard to prior exposure to GCs. Predictors of vertebral fracture in the placebo group were identified using Cox regression with forward selection. The BMD threshold analysis involved a comparison of the 1-year fracture risk in postmenopausal women receiving placebo in the GC trials with that in postmenopausal women not taking GCs in 3 other trials. RESULTS: The study population comprised 306 patients with baseline and 1-year followup data on vertebral fractures (111 receiving placebo and 195 receiving risedronate). In the placebo group, the statistically significant predictors of incident fracture were the baseline lumbar spine BMD (for each 1-point decrease in T score, relative risk [RR] 1.85, 95% confidence interval [95% CI] 1.06-3.21) and the daily GC dose (for each 10-mg dose increase, RR 1.62, 95% CI 1.11-2.36). In the BMD threshold analysis, compared with nonusers of GCs, patients receiving GCs were younger, had a higher BMD at baseline, and had fewer prevalent fractures; nevertheless, the risk of fracture was higher in the GC users compared with nonusers (adjusted RR 5.67, 95% CI 2.57-12.54). The increased risk of fracture was observed in GC users regardless of whether osteoporosis was present. CONCLUSION: The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prolonged GC treatments further worsen the bone quality [35, 55]”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [55]
In the citing paper
“The effect of hPTH (1-34) on hip fracture reduction has not been shown in clinical studies in GIOP populations. [55, 57].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [55]
Citations
Cites
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 3×
“Osteocyte apoptosis is prevalent in GC-induced osteoporosis (24), and preliminary results of an animal study demonstrated that osteocyte viability was an important determinant of bone strength independent of BMD (25).”
BackgroundResultReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Use of Inhaled Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297
Self-citationThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Self-citationUse of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citationDose-Response and Trend Analysis in Epidemiology
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,086
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. C. (2000) · Lara D. Veeken · doi:10.1093/rheumatology/39.12.1383 · Cited by 699
Self-citationEFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Reid, D. M., Hughes, R., Laan, R., Sacco-Gibson, N., Wenderoth, D., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 585
Self-citationUse of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Peel, N. F. A., Moore, D., Barrington, N. A., Bax, D. E., & Eastell, R. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.10.801 · Cited by 377
Rheumatoid arthritis, corticosteroid therapy and hip fracture.
Cooper, C. C., Coupland, C. A. C., & Mitchell, M. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.1.49 · Cited by 348
Self-citationFractures after rheumatoid arthritis a population‐based study
Hooyman, J. R., Melton, L. J., Nelson, A. M., O’Fallon, W. M., & Riggs, B. L. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780271205 · Cited by 283
Dykman, T. R., Gluck, O. S., Murphy, W. A., Hahn, T. J., & Hahn, B. H. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280402 · Cited by 281
Adverse effects of oral corticosteroids in relation to dose in patients with lung disease
Walsh, L. J. (2001) · Thorax · doi:10.1136/thorax.56.4.279 · Cited by 251
Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.
Luengo, M., Picado, C., del Río, L., Guañabens, N., Montserrat, J. M., & Setoaín, J. (1991) · Thorax · doi:10.1136/thx.46.11.803 · Cited by 241
Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability
Johnell, O., Odén, A., Laet, C. E. D. H. D., Garnero, P., Delmas, P. D., & Kanis, J. A. (2002) · Osteoporosis International · doi:10.1007/s001980200068 · Cited by 195
Vertebral Fracture Risk With Long-term Corticosteroid Therapy
Naganathan, V., Jones, G., Nash, P. T., Nicholson, G. C., Eisman, J. A., & Sambrook, P. N. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.19.2917 · Cited by 141
Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind
Manolagas, S. C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1001 · Cited by 135
Grados, F., Roux, C., de Vernejoul, M. C., Utard, G., Jl, S., & Fardellone, P. (2001) · Osteoporosis International · doi:10.1007/s001980170046 · Cited by 110
Corticosteroids Do Not Alter the Threshold for Vertebral Fracture
Selby, P. L., Halsey, J. P., Adams, K., Klimiuk, P. S., Knight, S. M., Pal, B., Stewart, I. M. G., & Swinson, D. R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.952 · Cited by 92
Guidelines for prevention and treatment of glucocorticoid-induced osteoporosis
Compston, J. E. (2009) · Bone · doi:10.1016/j.bone.2009.07.039 · Cited by 39
Ettinger, B. B., Pressman, A. R., & Shah, H. A. (2001) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2001.7.3.228 · Cited by 12
Griffiths, D. J., & Venables, P. J. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11 · Cited by 1
Self-citationSantiago (2001) · doi:10.1002/1529-0131(200107)44:7
Flagged first, then by citations
Research works printed but not linked: 3
- 1996, SAS/GRAPH software: reference version 6
- Johnell O, 2002, Oral corticosteroids increase fracture risk independently of BMD, Osteoporos Int, 13, S14
- Weinstein RS, 2002, Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid‐treated mice independently of BMD: an unappreciated determinant of bone strength, J Bone Miner Res, 17, S156
Cited by
Sorted by citations
Papaioannou, A., Morin, S. N., Cheung, A. M., Atkinson, S. A., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A. B., Jamal, S. A., Kaiser, S., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,768
Epidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,300
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,234
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
CANALIS, E. M., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,131
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2003) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Metadata
- Authors
- Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C.
- Affiliations
- Procter & Gamble (United Kingdom) (GB)
- University of Aberdeen (GB)
- University of Southampton (GB)
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-11
- Volume
- 48
- Issue
- 11
- Pages
- 3224-3229
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1978136096
- Cited by
- 559
- References
- 29
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 11 · 2023: 13 · 2022: 21 · 2021: 27 · 2020: 28 · 2019: 30 · 2018: 36 · 2017: 30 · 2016: 28 · 2015: 36 · 2014: 29 · 2013: 29 · 2012: 23
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arthritis & Rheumatism (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- vertebral fractures, oral corticosteroids, bone mineral density, fracture risk prediction, risedronate, postmenopausal women, glucocorticoid dose, osteoporosis, lumbar spine bone mineral density, T-score thresholds
- MeSH terms
- Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Femur Neck, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Prednisone, Risk, Risk Factors, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
